In postmenopausal women at high risk for fracture, romosozumab for 3 mo was noninferior to 12 mo for increasing total hip BMD at 1 y

Key Points

• This research aims to assess the effectiveness of romosozumab over different treatment durations in enhancing bone mineral density.
• Randomized trial design among postmenopausal women at high risk for fracture.
• Participants received either romosozumab for 3 months or 12 months.
• Bone mineral density was measured at the total hip after 1 year.
• Both treatment durations effectively increased total hip bone mineral density (BMD) at 1 year.
• The 3-month treatment was shown to be noninferior to the 12-month duration for BMD increase.